Table 6 Urinary excretion of CPT and creatinine clearance

From: A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours

 

Urinary excretiona (% of the dose)

Creatinine clearanceb (before treatment, ml min−1)

Cohort 1 (80 mg m−2)

 Patient 1

34.1

60.1

 Patient 2

56.2

90.3

 Patient 3

91.8

78.2

 Patient 7

60.3

48.5

 Patient 8

52.6

69.3

 Patient 9

55.4

45.1

 Mean±s.d.

58.4±18.8

65.3±17.5

Cohort 2 (120 mg m−2)

 Patient 4

26.4

82.8

 Patient 5

38.4

93.7

 Patient 6

40.5

76.9

 Mean±s.d.

35.1±7.6

84.5±8.5

  1. aValues obtained from the first 24 h of treatment (cycle 1).
  2. bValues calculated by Cockroft and Gault formula.